Overview
Isabl is a company that provides cancer tests based on whole genome and transcriptome data[1]. The company analyzes complete cancer patient genomes to provide clarity on tumor biology for treatment planning[1]. Founded in 2020, Isabl is headquartered in New York City, NY[2]. The company participated in the Y Combinator Winter 2020 batch[3].
Isabl has developed software that can analyze the entire genome of cancer patients. Today, when people get cancer, they get a genetic test of their tumor that analyzes only a few possible mutations. With Isabl, you run the tumor through an Illumina sequencer and get the whole genome, then our software is able to analyze all the mutations. Our breakthrough technology provides unprecedented clarity into tumor biology to aid treatment planning. This opens up opportunities for precision diagnostics, disease surveillance and biomarker discovery. [9]
Located in New York City, NY [2]
Y Combinator's directory lists the company location as New York City, NY, USA; New York, NY, USA; Remote. [6]
Business address: 175 Greenwich St, New York, New York, 10007. [10]
Growth & traction
Y Combinator lists a team size of 5. [8]
Backers
Two Sigma Ventures
NYC-based venture capital firm backing data-driven and AI companies
Something wrong or missing? Send an update. Fixed within 24 hours.